CTMC Began Pivotal Manufacturing for TIL Therapy Program
The Houston-based company has implemented a digital tracking system to support large-scale cell therapy production.
Updated on Oct. 1, 2026 in Biotech
Live Poll
Do you trust private-public partnerships to accelerate the development of new cancer therapies?
CTMC has commenced pivotal-stage manufacturing for a partner tumor-infiltrating lymphocyte (TIL) program in Houston. The company also integrated a digital chain-of-identity solution to track patient-specific manufacturing operations.
Why it matters
This development standardizes the production of engineered TILs to reduce variability in cell therapy manufacturing. It aims to broaden the range of starting materials available for these treatments, accelerating the path to clinical-grade output.
The proprietary manufacturing process produces engineered TILs in under 30 days. This utilizes a closed-loop system incorporating TR-41, a 4-1BB agonist for cell expansion, and TR-56, a defined feeder-cell line.
The players
CTMC
A Houston-based cell therapy developer that integrates regulatory, quality, and manufacturing operations within the Texas Medical Center.
Cancer Prevention and Research Institute of Texas
A state-funded organization that provides financial support for advanced research and infrastructure development in oncology.
The details
CTMC, based in the Texas Medical Center, utilizes an integrated model that bundles regulatory strategy with Good Manufacturing Practice (GMP) standards. To maintain compliance and accuracy, the firm deployed autoloMATE, a digital software solution that monitors the chain-of-identity and chain-of-custody for every patient-specific batch. The process relies on defined reagents and proprietary viral vectors—modified viruses used to deliver genetic material into cells—to eliminate the need for PBMC-derived (peripheral blood mononuclear cell) feeder cells, which are historically variable in clinical manufacturing.
Timeline
October 1, 2026: CTMC officially announced the commencement of pivotal-stage manufacturing.
The Tech Race
This effort builds upon research funding provided by the Cancer Prevention and Research Institute of Texas to scale complex cell-based therapies. It marks a shift from experimental bench work to controlled, scalable pivotal manufacturing.
This production model aims to stabilize the supply chain for advanced TIL therapies by using defined reagents rather than biological variants. These operational efficiencies are intended to support partners currently moving through pivotal clinical trials.
The takeaway
The move demonstrates a critical transition from lab-scale production to structured, reproducible manufacturing in cellular immunotherapy. Industry observers should track future updates on the performance of TR-41 and TR-56 in clinical trial outcomes as these processes reach wider patient populations.
Further reading
For more on the current landscape of Biotech, visit our dedicated section.
Live Poll
Do you trust private-public partnerships to accelerate the development of new cancer therapies?
